Quick Answer: NMN and NR are NAD+ precursors — they refuel your mitochondria by restoring a critical coenzyme that declines dramatically with age. Urolithin A works through an entirely different mechanism: it triggers mitophagy, the process of clearing out damaged mitochondria so healthier ones can replace them. They're not competing products. They target different problems in the same system. Of the three, Urolithin A currently has the strongest human RCT evidence for measurable physical performance outcomes. NMN and NR have strong evidence for raising NAD+ levels, with human functional data continuing to grow.
The longevity supplement category has exploded. Walk into any serious supplement store — or scroll through enough health content — and you'll encounter NMN, NR, and Urolithin A presented as interchangeable options in the "mitochondrial health" bucket. Some brands sell all three. Some influencers pick one and crown it the winner. Almost nobody explains what actually separates them.
That's a problem, because the differences are fundamental. These three compounds target the same downstream goal — healthier, more functional mitochondria — but they work through mechanisms so distinct that calling them "the same category" is like calling aspirin and surgery "the same treatment" because both address pain.
If you're serious about longevity supplementation, you need to understand what each compound actually does. This is that explanation.
The Shared Goal: Mitochondrial Health
Your mitochondria are not just the powerhouses of the cell — that phrase has become so overused it's lost its meaning. The more precise framing: mitochondria are the reason you age the way you do.
They generate ATP, the cellular currency that powers every biological process in your body. They regulate calcium signaling, apoptosis (programmed cell death), and reactive oxygen species (ROS) production. They are deeply integrated into the inflammatory signaling networks that determine how fast your tissues deteriorate.
And they decline. Mitochondrial function drops measurably with age, and that decline shows up as reduced energy production, impaired muscle function, slower recovery, metabolic dysregulation, and accelerated cellular aging. The research linking mitochondrial dysfunction to the hallmarks of aging is now robust enough that mitochondrial health has become a central target of serious longevity science.
NMN, NR, and Urolithin A all target this system. But the way they intervene could not be more different.
NMN (Nicotinamide Mononucleotide)
What it is
NMN is a nucleotide — a building block compound found naturally in small amounts in foods like edamame, broccoli, and cucumber. As a supplement, it functions as a direct precursor to NAD+ (nicotinamide adenine dinucleotide).
The mechanism
NAD+ is a coenzyme required for hundreds of enzymatic reactions. Two categories matter most for longevity:
Sirtuins (SIRT1, SIRT3, SIRT5, SIRT6): NAD+-dependent deacetylases that regulate gene expression, DNA repair, inflammation, and mitochondrial biogenesis. SIRT1 activates PGC-1α, the master regulator of mitochondrial biogenesis — essentially telling cells to make more mitochondria. SIRT3 is mitochondria-specific, regulating oxidative phosphorylation and antioxidant defense inside the mitochondria themselves.
PARP enzymes: NAD+-consuming DNA repair enzymes. When DNA damage occurs — from oxidative stress, radiation, or normal metabolic byproducts — PARP enzymes are recruited to repair it. They require NAD+ to function. As we age and accumulate more DNA damage, PARP activity can compete aggressively with sirtuins for the available NAD+ pool, which is already shrinking.
The problem NMN addresses: NAD+ levels decline approximately 50% between age 20 and age 50. This is well-established across multiple human studies. NMN → converted via NMN adenylyltransferase (NMNAT) enzymes in tissues → NAD+. By providing more NMN, the theory is that you can restore declining NAD+ levels and with them, the sirtuin and DNA repair activity that depends on them.
What the human trials show
Yoshino et al., 2021 (Science): 25 postmenopausal women with prediabetes received 250mg NMN daily for 10 weeks in a double-blind, placebo-controlled trial. The primary finding: NMN significantly improved skeletal muscle insulin sensitivity. The mechanism appeared to be enhanced expression of genes involved in muscle remodeling and insulin signaling. This is a meaningful human functional outcome — not just a biomarker change.
Igarashi et al., 2022 (npj Aging): Older men given NMN showed improvements in muscle function, measured by grip strength and walking speed. Small study, but directionally consistent with the hypothesis.
Multiple trials confirming NAD+ elevation: Several well-controlled human studies have confirmed that oral NMN reliably raises blood NAD+ levels. The doses studied range from 250mg to 1200mg daily.
The honest caveats
Most of the dramatic NMN results — extended lifespan, reversed aging phenotypes, dramatic metabolic restoration — come from rodent studies. Mice metabolize NMN differently than humans, and their lifespans make long-term studies more tractable. The human data is genuinely promising but not yet conclusive for most functional outcomes beyond insulin sensitivity and NAD+ elevation.
There is also an ongoing scientific debate about whether oral NMN reaches target tissues effectively, or whether it is largely converted to NR in the gut before absorption. The bioavailability question has been addressed in part by newer delivery forms (sublingual, liposomal), but the head-to-head tissue distribution data in humans is not yet comprehensive.
NR (Nicotinamide Riboside)
What it is
NR is another NAD+ precursor, structurally similar to NMN but at a slightly earlier point in the synthesis pathway. NR is converted to NMN, which is then converted to NAD+. NR is also found naturally in trace amounts in milk.
The mechanism
The pathway: NR → NMN (via NRK1/2 enzymes) → NAD+ (via NMNAT). Because NR requires one additional enzymatic step compared to NMN, some researchers have argued that NMN should have superior conversion efficiency — but in practice, the tissue distribution and cellular uptake of these compounds is more complex than a simple conversion chain suggests, and the differences in human studies have not been dramatic.
Both NR and NMN activate the same downstream biology: NAD+ dependent sirtuins, DNA repair, and mitochondrial biogenesis via PGC-1α.
What the human trials show
Elhassan et al., 2019 (Cell Reports): 500mg NR daily significantly raised blood NAD+ metabolite levels in healthy middle-aged adults. This was one of the cleaner human NAD+ elevation studies, with well-controlled design.
Martens et al., 2018 (Nature Communications): 500mg NR daily in older adults (55–79 years) over 6 weeks. NAD+ metabolism was significantly upregulated. There was a trend toward reduced aortic stiffness, though this did not reach statistical significance in the study size. No significant changes in blood pressure, arterial stiffness, or other cardiovascular markers.
Dollerup et al., 2018 (American Journal of Clinical Nutrition): 1000mg NR daily in obese men for 12 weeks. NAD+ levels rose significantly. No statistically significant effects on insulin sensitivity in this population, though the study was not powered specifically for that outcome.
The pattern across NR studies: consistent NAD+ elevation, mixed and often non-significant results for functional outcomes. The gap between raising NAD+ in blood and improving functional outcomes in target tissues is real and not yet fully explained.
NMN vs. NR: which is better?
Honestly, the human data doesn't decisively separate them. Both raise NAD+. Both are well-tolerated. NMN has the edge in recent trials for functional muscle outcomes (Yoshino 2021). NR has a longer track record in humans and more published safety data. The mechanistic difference (NMN is one step closer to NAD+) likely matters less than dose, form, and individual metabolic context. Anyone selling you certainty on which is definitively superior is ahead of the current evidence.
Urolithin A
What it is
Urolithin A is a metabolite produced when gut bacteria ferment ellagitannins — polyphenols found in pomegranate, walnuts, and certain berries. Critically, only about 30–40% of people can produce Urolithin A efficiently from food sources, depending on their gut microbiome composition. Supplemental Urolithin A (as Mitopure, the most studied form) bypasses the microbiome dependency and delivers the compound directly.
The mechanism
Here is where Urolithin A fundamentally diverges from NMN and NR.
NMN and NR refuel your mitochondria — they restore the NAD+ supply that aging has depleted, allowing the mitochondria you have to function better.
Urolithin A does something different: it activates mitophagy — the selective autophagy process by which cells identify, tag, and remove damaged mitochondria.
The pathway: Urolithin A upregulates the PINK1/Parkin signaling cascade. When a mitochondrion loses its membrane potential (a sign of damage), PINK1 accumulates on its outer membrane, recruits Parkin, and marks it for degradation. The cell then wraps the damaged mitochondrion in an autophagosome and digests it. Mitophagy is quality control — clearing the debris so healthy mitochondria can replicate and take over.
The analogy that makes this intuitive: NMN and NR fill the gas tank. Urolithin A replaces the broken engine.
Both interventions are legitimate. A car with a dirty but intact engine benefits from a fuel supply chain fix. A car with a failing engine needs the engine replaced. Real mitochondrial aging involves both problems.
What the human trials show
This is where Urolithin A genuinely stands apart from NMN and NR in terms of current human evidence.
Andreux et al., 2019 (Nature Metabolism): First-in-human clinical trial of Mitopure (500mg, 1000mg, 2000mg Urolithin A). Randomized, double-blind, placebo-controlled. Found significant upregulation of mitophagy and mitochondrial gene expression in muscle biopsies at 1000mg and 2000mg doses. This confirmed that oral Urolithin A reaches muscle tissue, activates mitophagy at the molecular level, and is safe and well-tolerated at doses up to 2000mg.
Singh et al., 2022 (Cell Reports Medicine): Randomized, double-blind, placebo-controlled trial. 66 older adults (65–90 years) received 1000mg Urolithin A (Mitopure) or placebo for 4 months. Primary outcome: muscle endurance, measured by hand grip and fatigue resistance. Result: significantly improved muscle endurance in the Urolithin A group. This is a hard human RCT showing a measurable physical performance outcome — the kind of evidence NMN and NR are still building toward.
Liu et al., 2022 (European Journal of Sport Science): Middle-aged adults, 500mg Urolithin A, 4 weeks. Significantly improved aerobic performance (VO2 max equivalent measures) compared to placebo.
Urolithin A currently has the most direct human RCT evidence for a functional physical performance outcome of the three compounds discussed here.
The Comparison Matrix
| NMN | NR | Urolithin A | |
|---|---|---|---|
| Primary mechanism | NAD+ precursor (direct) | NAD+ precursor (indirect) | Mitophagy activator |
| Target problem | NAD+ depletion | NAD+ depletion | Accumulation of damaged mitochondria |
| Key pathway | NMNAT → NAD+ → sirtuins, PARP | NRK → NMN → NAD+ → sirtuins, PARP | PINK1/Parkin → selective mitochondrial clearance |
| Human NAD+ elevation | Confirmed | Confirmed (more studies) | Not the mechanism |
| Human functional outcomes | Muscle insulin sensitivity (Yoshino 2021) | Trend toward cardiovascular (Martens 2018) | Muscle endurance, aerobic performance (Singh 2022, Liu 2022) |
| Strength of human RCT evidence | Moderate | Moderate | Strongest for physical performance |
| Complementary or competing? | Complementary | Complementary | Complementary |
Why These Are Complementary, Not Competing
The three compounds address different nodes in the same system, which is why intelligent supplementation often involves combining them rather than choosing between them.
Think of mitochondrial aging as having two distinct problems:
Problem 1: Declining fuel supply. NAD+ drops with age. Sirtuins lose activity. DNA repair slows. Mitochondrial biogenesis through PGC-1α decreases. Your mitochondria don't have the resources they need to function. This is what NMN and NR address.
Problem 2: Accumulating damaged mitochondria. With age, mitophagy becomes less efficient. Damaged, dysfunctional mitochondria accumulate rather than being cleared. This contributes to increased ROS production and chronic low-grade inflammation. This is what Urolithin A addresses.
Now consider the interaction: NAD+ is itself required to fuel the autophagy process. Mitophagy demands ATP, and ATP demands mitochondrial function, and mitochondrial function requires NAD+. This means NMN or NR can enhance the effectiveness of Urolithin A by ensuring there's sufficient NAD+ to power the cellular cleanup process.
The layered protocol logic: - Urolithin A → activates mitophagy → clears damaged mitochondria → reduces cellular dysfunction and ROS accumulation - NMN or NR → restores NAD+ → supports sirtuin activity, DNA repair, and mitochondrial biogenesis → provides the fuel supply for the mitophagy process itself and for new healthy mitochondria to function optimally
These are not redundant. They are sequentially and mechanistically linked.
The Honest Evidence Assessment
A fair summary of where the science actually stands:
Urolithin A has the strongest current human RCT evidence for a measurable functional physical outcome (muscle endurance). The Andreux 2019 and Singh 2022 trials are well-designed, peer-reviewed, and published in high-tier journals. Mitopure is a rigorously studied form.
NMN has strong evidence for raising NAD+ and meaningful evidence for improving insulin sensitivity in a relevant population (Yoshino 2021). Human trials are growing, and the mechanistic rationale is solid.
NR has the most human safety data accumulated over time and consistent evidence for NAD+ elevation. Functional outcome data in humans is less consistent, though the mechanistic pathway is well-established.
What none of these have: long-term longitudinal human safety data across decades, or clear evidence of extended human lifespan. These are relatively new interventions studied in relatively short time windows. The rodent data is exciting and directionally consistent. The human data is promising and growing. Anyone claiming certainty about 20-year outcomes is not reading the literature carefully.
All three compounds are well-tolerated in published studies. No serious adverse effects have emerged at commonly studied doses. This is meaningful — not nothing.
Frequently Asked Questions
Is NMN or NR better? The current human evidence doesn't decisively favor one over the other. Both raise NAD+ reliably. NMN may have a slight edge for muscle-specific insulin sensitivity (Yoshino 2021). NR has more accumulated human safety data. In practice, the difference in outcomes for most people is likely small. Dose, form quality, and consistency of use probably matter more than which precursor you choose.
What is the difference between NMN and urolithin A? Fundamentally different mechanisms. NMN is a NAD+ precursor — it restores the coenzyme your mitochondria need to function. Urolithin A is a mitophagy activator — it triggers the removal of damaged mitochondria. NMN fuels the system you have. Urolithin A helps replace the parts of the system that have broken down.
Do longevity supplements actually work? It depends on what "work" means. All three compounds have evidence that they activate their intended mechanisms in human subjects. Urolithin A has evidence for a measurable physical performance improvement. NMN has evidence for improved insulin sensitivity. Whether they extend human lifespan is unknown — the trials needed to establish that haven't been conducted. They are biologically active compounds that target well-validated aging mechanisms. That is a reasonable foundation for use.
What dose of NMN is effective? Studies have shown effects at doses ranging from 250mg to 1200mg daily. The Yoshino 2021 trial used 250mg with positive results. Most consumer products fall in the 300–600mg range. There is no clearly established optimal dose for all purposes.
Can you take NMN and urolithin A together? Yes. They target different mechanisms and there are no known adverse interactions. There is a theoretical basis for synergy: NAD+ (boosted by NMN) supports the autophagy process activated by Urolithin A. Many longevity-oriented practitioners and researchers use both.
Which longevity supplement has the most human evidence? Urolithin A currently has the strongest human RCT evidence for a measurable physical performance outcome — specifically muscle endurance (Singh 2022). NMN and NR have more evidence for a specific biomarker (NAD+ elevation) but less evidence for downstream functional outcomes in humans to date.
Key Takeaways
- NMN and NR are both NAD+ precursors. They work by restoring declining NAD+ levels, which supports sirtuin activity, DNA repair, and mitochondrial biogenesis. They address a fuel supply problem.
- Urolithin A is a mitophagy activator. It works by triggering the removal of damaged mitochondria via the PINK1/Parkin pathway. It addresses a quality control problem.
- All three target mitochondrial health but through fundamentally different mechanisms — making them complementary rather than competing.
- Urolithin A currently has the strongest human RCT evidence for a measurable physical outcome (muscle endurance). NMN leads among the NAD+ precursors for functional human data.
- None of these have long-term longitudinal human safety or longevity data. The mechanistic rationale is strong; the 20-year outcome data doesn't exist yet.
- The most comprehensive approach uses both NAD+ precursors and Urolithin A to address different problems in the same aging system.
Related Reading
- Urolithin A: What the Research Actually Shows About Mitophagy and Muscle Function
- NAD+ and Aging: Why This Molecule Matters More Than Most People Know
- How to Build a Longevity Stack: The Evidence-Based Approach
- Mitochondria and Energy: Why Your Cells' Power Plants Determine How You Age
Evidence References
- Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229.
- Igarashi M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. npj Aging. 2022;8(1):5.
- Elhassan YS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Reports. 2019;28(7):1717–1728.
- Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018;9(1):1286.
- Andreux PA, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism. 2019;1(6):595–603.
- Singh A, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine. 2022;3(5):100633.
- Liu S, et al. Urolithin A improves endurance exercise performance via stimulating mitophagy in middle-aged males. European Journal of Sport Science. 2022;23(7):1461–1473.
- Dollerup OL, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. American Journal of Clinical Nutrition. 2018;108(2):343–353.
- Bai P, et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metabolism. 2011;13(4):461–468.
- Mouchiroud L, et al. The NAD+/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell. 2013;154(2):430–441.
